So, we might as well do something with it, collect the tax dollars, and ultimately get the regulatory in place where you’re getting products out there that go through regulatory that are not cut with other drugs or other ingredients out there that are not safe. In regards to what ultimately the opportunities are for Tilray, listen, if one day, and again, this is hope, no reason to believe, if we could grow it in Canada and ship it into the U.S. is an opportunity for us. We have a big medical business in Europe. We have a medical business in Canada, which ultimately would get us into the business here in the U.S. So, I think first, there is ultimately no benefit to Tilray. I don’t think anything is going to happen here for a little while, for over the next two years anyway, but it would basically be very, very, very good for the cannabis industry.
John Zamparo: Okay, great. I’ll leave it at that. Thank you.
Operator: Thank you. That concludes our analyst questions. We’ll now proceed with questions submitted by retail stockholders on the Say Technologies platform. The question reads, why should we keep investing in Tilray?
Irwin Simon: Listen, again, I hope by our results today and some of the things that we’re doing, that number one, investors believe in the management team and believe in our strategy. Some don’t believe in our strategy, but I will tell you, we have a defined strategy, we have a structured strategy with a lot of process and a lot of levers there that we’re ultimately pulling to have a structured strategy. We are, secondly, a very diversified business, but ultimately how do they all come together under one common denominator. We’re not just a cluster of a bunch of products, brands, and categories. And, upon legalization, we have multiple brands that can convert to cannabis. Ultimately, we have tremendous amount of grow. We have tremendous amount of production today.
With our beer and our spirits business, we are one of the only ones with two cannabis grow facilities in Europe where we have a great medical platform. So, we’re different than most other cannabis companies, we’re different than most other craft beer businesses, we’re different than any other healthier food business with our hemp Manitoba Harvest. So, we’re absolutely different. We’re a big believer in building brands, brand equity, brand equity, brand equity. And there’s a lot of work we have to do on our brands in Canada and make consumers familiar with our brands. Again, cannabis has only been there for five years. And again, it’s educating the consumers on the brands. And listen, it’s hard to build brands when you’re not legally allowed to advertise in the Canadian market to consumers.
But we have to do that. Number two, we’ve got some great brands in regards to beer. We got great brands in regards to Breckenridge Bourbon and Manitoba Harvest, and we have a really, really strong relationships with doctors and distributors in the European market in regards to our medical business. Tilray Pharma, which was CC Pharma, is a distributor that distributes into 13,000 drug stores. We’re looking to convert that business and working with other distributors throughout Europe of how we increase margins. Just think about it that’s a $300 million business and every margin dollar that we increase there is a major contribution to our bottom-line. So with that we have a strategy. We are about making money and managing our balance sheet. Will it take some time to come together?
It absolutely has been. But I’ll tell you, the components are there. And I think that’s what’s different and unique. And that’s why I hope our investors stay with us. And those that are, thank you very much. That is the questions for today. I want thank all that have joined the call, all that have gone online to listen to us. Listen, I can reassure you this here, the cannabis industry is a tough industry. The beer industry is a tough industry. But there’s no business, there’s no industry out there that’s not tough. But what’s important today is that you have a team that knows how to deal with the toughness, knows how to deal with the environment. And today, with the acquisition of the Anheuser-Busch businesses, we have close to 2,300 employees around the world that are working hard every day.
